Trium Capital discloses 10.86% stake in Mural Oncology
PositiveFinancial Markets

Trium Capital has announced a significant investment by acquiring a 10.86% stake in Mural Oncology. This move highlights Trium's confidence in Mural's innovative approach to cancer treatment, which could lead to advancements in the field and potentially improve patient outcomes. Such investments are crucial as they not only provide financial backing but also signal to the market the potential of Mural's therapies.
— Curated by the World Pulse Now AI Editorial System